Search results for: Multi-Indication Medicines
Filter search results
Two numbers, one decision: making climate-health valuation usable across sectors
18 May 2026
…derived from individuals’ willingness to pay for small reductions in the probability of sudden death, typically through wage-risk studies and stated-preference surveys. Multiplied across populations, it is what makes a…
Gundo Weiler
22 June 2026
…Europe, Africa and Asia to develop integrated approaches to health, development and emergencies. Prior to joining the Regional Office for Europe, Gundo served in multiple roles in WHO’s Western Pacific…
World EPA Congress 2027
2 March 2027, 9:00am
World Evidence, Pricing and Access Congress is Europe’s largest conference in market access, pricing and evidence featuring 300 speakers, multiple streams and over 1500 attendees from pharma, biotech and Payers/HTAs….
Sayuri Rentschler
10 September 2026
…a BSc in Economics from Albert Ludwigs University of Freiburg, Germany. Her research interests include health behaviours, vaccine policy, and broader global health challenges. She has gained experience across multiple sectors including pharmaceutical, finance, NGOs, and…
The economic burden of overweight and obesity in Europe
24 September 2026
…risk factor for serious comorbidities Obesity is a chronic, complex, multifactorial, relapsing disease characterised by excess body fat that has detrimental health consequences (WHO, 2025a). It is estimated that half of…
Dr Claus Runge
24 September 2026
…local and global level in various multinational companies, such as GSK, Wyeth and AstraZeneca. In his career, he has been responsible for a broad span of functions, including Commercial, Pricing…
Enya Hughes
21 October 2026
…She is interested in delivering reliable, engaging, and relevant multimedia content to audiences, and helping brand voices stand out in the evolving global media and communications landscape. Enya holds an MPhil…
OHE at ISPOR Europe 2026
8 November 2026, 12:00am
…Biologic Therapies in Multiple Myeloma: The Potential of On-Body Injectors to Improve Healthcare Efficiency and Service Delivery Henry Fong 10:30-13:30 Poster Session 1 HEOR Impact Cases Poster Tour Chris Skedgel…
Can the US Afford to Ignore Cost-Effectiveness Evidence in Health Care?
23 July 2013, 11:00pm
…Dr Chambers noted whether its coverage decisions for medicines are consistent with cost-effectiveness evidence. He also discussed the potential benefits of including economic evidence in Medicare coverage policy in terms…